Back to top
more

Amneal Pharmaceuticals (AMRX)

(Delayed Data from NSDQ)

$5.90 USD

5.90
3,428,180

-0.15 (-2.48%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $5.91 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AMRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for AMNEAL PHARMACEUTICALS, INC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 99 35 257 347 153
Receivables 615 742 664 640 606
Notes Receivable 0 0 0 0 0
Inventories 581 531 489 491 381
Other Current Assets 83 104 110 73 70
Total Current Assets 1,378 1,412 1,520 1,552 1,210
Net Property & Equipment 448 470 514 478 478
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1,489 1,695 1,760 1,827 1,802
Deposits & Other Assets 56 103 21 32 44
Total Assets 3,473 3,799 3,940 4,006 3,666
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 1 0
Accounts Payable 535 538 583 614 507
Current Portion Long-Term Debt 213 90 31 44 21
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 84 110 48 8 6
Total Current Liabilities 847 753 677 677 550
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,427 2,632 2,718 2,772 2,609
Non-Current Capital Leases 0 0 0 60 61
Other Non-Current Liabilities 42 97 49 87 40
Minority Interest (Liabilities) 41 25 17 12 0
Total Liabilities 3,453 3,615 3,573 3,661 3,319
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 3 3 3 3 3
Capital Surplus 539 692 658 628 607
Retained Earnings -490 -406 -276 -287 -378
Other Equity -32 -105 -18 0 115
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 20 184 367 345 347
Total Liabilities & Shareholder's Equity 3,473 3,799 3,940 4,006 3,666
Total Common Equity 20 184 367 345 347
Shares Outstanding 306.50 303.60 301.50 299.70 299.10
Book Value Per Share 0.07 0.61 1.22 1.15 1.16

Fiscal Year End for AMNEAL PHARMACEUTICALS, INC falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 99 96 115 151
Receivables NA 615 693 675 546
Notes Receivable NA 0 0 0 0
Inventories NA 581 576 551 529
Other Current Assets NA 83 91 82 81
Total Current Assets NA 1,378 1,456 1,422 1,307
Net Property & Equipment NA 448 452 459 463
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 1,489 1,581 1,615 1,654
Deposits & Other Assets NA 56 89 93 86
Total Assets NA 3,473 3,687 3,701 3,627
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 535 558 513 467
Current Portion Long-Term Debt NA 213 107 150 130
Current Portion Capital Leases NA 0 0 3 3
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 84 80 98 15
Total Current Liabilities NA 847 761 777 704
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 2,427 2,583 2,590 2,602
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 53 48 53
Minority Interest (Liabilities) NA 41 37 32 28
Total Liabilities NA 3,453 3,533 3,550 3,492
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 3 3 3 3
Capital Surplus NA 539 715 708 701
Retained Earnings NA -490 -392 -401 -413
Other Equity NA -32 -173 -159 -156
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 20 154 151 135
Total Liabilities & Shareholder's Equity NA 3,473 3,687 3,701 3,627
Total Common Equity 0 20 154 151 135
Shares Outstanding 307.00 306.50 306.40 306.10 305.40
Book Value Per Share 0.00 0.07 0.50 0.49 0.44